An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy

Acar N. P. , Tuncer A., Ozkazanc D., Ozbay F. G. , KARAOSMANOĞLU B. , Goksen S., ...Daha Fazla

JOURNAL OF NEUROIMMUNOLOGY, cilt.347, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier


This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon-beta 1 and fingolimod therapies. Fingolimod reduced the CD56(bright) NK cell subset. The remaining CD56(dim) NK cells displayed NKG2D, NKp46, CD107a, and IFN-gamma levels similar to those from the patients under interferon-beta 1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed significant distinctions between two therapy modalities. Molecular signature of the CD56(dim) NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects. The basic assets of NK cells were modestly influenced by interferon-beta 1 and fingolimod, however transcriptomics showed profound alterations in NK responses.